While near-normal glucose levels can be hypothetically achieved by the use of novel insulins under control of advanced insulin delivery devices, and modern and accurate glucose-monitoring systems, it appears that glucose control alone is not sufficient to reduce the overall health burden associated with T1D. The gene discussed is INS; the disease is type 1 diabetes mellitus.